Biocryst Pharmaceuticals (BCRX) Income from Continuing Operations: 2010-2015
Historic Income from Continuing Operations for Biocryst Pharmaceuticals (BCRX) over the last 4 years, with Sep 2015 value amounting to -$14.3 million.
- Biocryst Pharmaceuticals' Income from Continuing Operations fell 11.36% to -$14.3 million in Q3 2015 from the same period last year, while for Sep 2015 it was -$42.2 million, marking a year-over-year decrease of 0.88%. This contributed to the annual value of -$50.7 million for FY2014, which is 43.14% down from last year.
- Per Biocryst Pharmaceuticals' latest filing, its Income from Continuing Operations stood at -$14.3 million for Q3 2015, which was down 443.67% from $4.2 million recorded in Q2 2015.
- In the past 5 years, Biocryst Pharmaceuticals' Income from Continuing Operations ranged from a high of $4.2 million in Q2 2015 and a low of -$16.4 million during Q4 2014.
- Its 3-year average for Income from Continuing Operations is -$10.2 million, with a median of -$12.8 million in 2014.
- As far as peak fluctuations go, Biocryst Pharmaceuticals' Income from Continuing Operations plummeted by 117.43% in 2014, and later spiked by 132.37% in 2015.
- Over the past 5 years, Biocryst Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at -$12.1 million in 2011, then grew by 3.47% to -$11.3 million in 2012, then fell by 17.79% to -$7.6 million in 2013, then tumbled by 117.43% to -$16.4 million in 2014, then decreased by 11.36% to -$14.3 million in 2015.
- Its Income from Continuing Operations was -$14.3 million in Q3 2015, compared to $4.2 million in Q2 2015 and -$15.6 million in Q1 2015.